RGLS
Price
$8.22
Change
+$0.12 (+1.48%)
Updated
Jun 6 closing price
Capitalization
569.1M
64 days until earnings call
SABS
Price
$1.81
Change
-$0.02 (-1.09%)
Updated
Jun 6 closing price
Capitalization
16.82M
Interact to see
Advertisement

RGLS vs SABS

Header iconRGLS vs SABS Comparison
Open Charts RGLS vs SABSBanner chart's image
Regulus Therapeutics
Price$8.22
Change+$0.12 (+1.48%)
Volume$2.78M
Capitalization569.1M
SAB Biotherapeutics
Price$1.81
Change-$0.02 (-1.09%)
Volume$2.41K
Capitalization16.82M
RGLS vs SABS Comparison Chart
Loading...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGLS vs. SABS commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGLS is a Hold and SABS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (RGLS: $8.22 vs. SABS: $1.81)
Brand notoriety: RGLS and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGLS: 147% vs. SABS: 5%
Market capitalization -- RGLS: $569.1M vs. SABS: $16.82M
RGLS [@Biotechnology] is valued at $569.1M. SABS’s [@Biotechnology] market capitalization is $16.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $334.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGLS’s FA Score shows that 0 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • RGLS’s FA Score: 0 green, 5 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, both RGLS and SABS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGLS’s TA Score shows that 3 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).

  • RGLS’s TA Score: 3 bullish, 4 bearish.
  • SABS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SABS is a better buy in the short-term than RGLS.

Price Growth

RGLS (@Biotechnology) experienced а +3.66% price change this week, while SABS (@Biotechnology) price change was -6.22% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

RGLS is expected to report earnings on Aug 12, 2025.

SABS is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGLS($569M) has a higher market cap than SABS($16.8M). RGLS YTD gains are higher at: 420.253 vs. SABS (-52.296). SABS has higher annual earnings (EBITDA): -40.29M vs. RGLS (-47.08M). RGLS has more cash in the bank: 65.4M vs. SABS (30.4M). RGLS has less debt than SABS: RGLS (1.4M) vs SABS (4.52M). RGLS (0) and SABS (0) have equivalent revenues.
RGLSSABSRGLS / SABS
Capitalization569M16.8M3,387%
EBITDA-47.08M-40.29M117%
Gain YTD420.253-52.296-804%
P/E RatioN/AN/A-
Revenue00-
Total Cash65.4M30.4M215%
Total Debt1.4M4.52M31%
FUNDAMENTALS RATINGS
RGLS: Fundamental Ratings
RGLS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
PROFIT vs RISK RATING
1..100
95
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RGLSSABS
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
74%
Momentum
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
56%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
67%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 11 days ago
71%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SABS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LADTX28.250.42
+1.51%
Lord Abbett Developing Growth R5
MAPLX26.950.31
+1.16%
Morgan Stanley Inst Advantage L
PJFAX61.860.51
+0.83%
PGIM Jennison Growth A
ACMTX10.030.05
+0.50%
AB All Market Real Return C
VIOAX9.560.04
+0.42%
VELA Income Opportunities A

RGLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGLS has been loosely correlated with ABEO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RGLS jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
+1.48%
ABEO - RGLS
45%
Loosely correlated
+4.01%
NKTX - RGLS
32%
Poorly correlated
+3.83%
ATOS - RGLS
31%
Poorly correlated
+4.69%
NAUT - RGLS
30%
Poorly correlated
+3.64%
LENZ - RGLS
30%
Poorly correlated
+5.48%
More